Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer crawled time : 08:20 save search
Final Multivariate Analysis from the Phase 3 MAGNITUDE Study Shows Trend Toward Improvement in Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer with BRCA Alterations Treated with Niraparib and Abiraterone Acetate Plus Prednisone
Published: 2023-10-22 (Crawled : 08:20) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
| Email alert
Add to watchlist
cancer plus study
TAR-200 Intravesical Delivery System Results Show 77 Percent Complete Response Rate in Patients with Bacillus-Calmette-Guérin Unresponsive, High-Risk Non-Muscle-Invasive Bladder Cancer
Published: 2023-10-22 (Crawled : 08:20) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
| Email alert
Add to watchlist
tar-200 bladder cancer system response results show
First Results with Erdafitinib-Releasing Intravesical Delivery System (TAR-210) Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations
Published: 2023-10-22 (Crawled : 08:20) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
| Email alert
Add to watchlist
tar-210 bladder positive cancer system results show growth
Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with BALVERSA® (erdafitinib) Versus Chemotherapy
Published: 2023-10-21 (Crawled : 08:20) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
| Email alert
Add to watchlist
balversa bladder cancer results show growth study
Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Biomarker-Selected Clinical Trial of MM-121 in Patients with Heregulin Positive Non-Small Cell Lung Cancer
Published: 2015-02-19 (Crawled : 08:20) - globenewswire.com
MACK 4 | $14.685 0.03% 0.03% 110K
|
Health Technology
| Email alert
Add to watchlist
phase 2 lung cancer positive cancer trial mm-120 biomarkers
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.